Summary
Terodiline chloride, 150 mg daily, was administered to 10 patients with obstructive pulmonary disease, and pulmonary function tests were performed before and during two weeks of therapy. Serious side effects of anticholinergic type developed in two patients who stopped treatment. Two patients were excluded from the trial for other reasons. The remaining six patients showed signs of bronchodilation. Owing to the high incidence of side effects, treatment with more than 75 mg terodiline chloride per day is impracticable.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Iravani, J.: Antagonismus zwischen Terodilin (Bicor) und Acetylcholin an der Bronchialmuskulatur der Ratte. In press (1974)
Lecerof, H., Malmborg, R.O.: Central hemodynamic effects of terodiline in patients with coronary heart disease. Acta med. scand.186 231–234 (1969)
Nisell, J.: Personal communication
Pepine, C. J., Wiener, L.: Relationship of anginal symptoms to lung mechanics during myocardial ischemia. Circulation46 863–869 (1972)
Ulmer, W.T.: Personal communication
Vessman, J., Strömberg, S.: Determination of terodiline (Bicor®) in serum by gas chromatography and electron capture detection of benzophenone formed by chromic acid oxidation. Acta pharm. suec.6 508–518 (1969)
Wibell, L.: Some aspects of the treatment of angina pectoris with presentation of terodiline, a new drug. Opusc. med. (Stockh.)13 78 (1968 a)
Wibell, L.: Terodiline in angina pectoris — a controlled study of a new drug. Acta Soc. Med. upsalien.73 75 (1968 b)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Castenfors, H., Hedenstierna, G. & Glenne, P.O. Pilot study of the effect of terodiline chloride (Bicor®) in obstructive pulmonary disease. Eur J Clin Pharmacol 8, 197–200 (1975). https://doi.org/10.1007/BF00567114
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00567114